News articles about AstraZeneca (NYSE:AZN) have trended very positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AstraZeneca earned a coverage optimism score of 3.33 on their scale. InfoTrie also gave news headlines about the company an news buzz score of 0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have impacted AstraZeneca’s ranking:
- AstraZeneca (NYSE:AZN) Earns Media Sentiment Score of 3.33 (americanbankingnews.com)
- AstraZeneca/Merck’s Selumetinib NDA Gets FDA Priority Status – Nasdaq (nasdaq.com)
- AstraZeneca combo diabetes drug Qtrilmet approved in Europe – The Pharma Letter (thepharmaletter.com)
- AstraZeneca: European Commission Approves Qtrilmet For Type-2 Diabetes – Nasdaq (nasdaq.com)
- AstraZeneca’s selumetinib moves past cancer failures to nab FDA priority review in neurofibromatosis – FiercePharma (fiercepharma.com)
Several brokerages recently commented on AZN. Credit Suisse Group reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, October 25th. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, November 8th. Liberum Capital raised AstraZeneca from a “hold” rating to a “buy” rating in a report on Friday, October 25th. Argus lifted their price objective on AstraZeneca to $50.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. Finally, Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a report on Friday, November 8th. Four analysts have rated the stock with a sell rating, five have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $46.53.
AstraZeneca (NYSE:AZN) last released its quarterly earnings results on Thursday, October 24th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.45 by $0.05. AstraZeneca had a return on equity of 38.63% and a net margin of 8.42%. The business had revenue of $6.13 billion during the quarter, compared to analyst estimates of $6.07 billion. During the same quarter in the previous year, the company posted $0.71 earnings per share. AstraZeneca’s revenue for the quarter was up 14.8% on a year-over-year basis. Equities analysts forecast that AstraZeneca will post 1.81 earnings per share for the current fiscal year.
In related news, major shareholder Plc Astrazeneca purchased 425,000 shares of the business’s stock in a transaction on Monday, October 7th. The stock was acquired at an average price of $19.00 per share, with a total value of $8,075,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: Dividend Aristocrat Index
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.